Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Q-linea AB ( (SE:QLINEA) ) is now available.
Q-linea has announced a reshaping of its US commercial leadership, with VP US Commercial Operations Jim Kathrein set to step down and support a transition during the first quarter of 2026, while Ethan Suttles, currently US Director of Strategic Accounts, will assume leadership of the US sales team and report directly to CEO Stuart Gander from 1 February 2026. The company is consolidating its US-based global leadership structure by having Natalie Brown, Director Global Marketing, and Vikas Gupta, Senior Director of Clinical Affairs, report directly to the CEO as well, underscoring a sharpened focus on executing Q-linea’s commercial strategy in the key US diagnostics market and accelerating the conversion of its growing ASTar® pipeline into routine clinical use heading into 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Swedish infection diagnostics company focused on rapid antibiotic susceptibility testing (rAST) to support timely treatment of sepsis and other severe infections. Its flagship product, the fully automated ASTar® system, delivers rapid phenotypic AST results directly from positive blood cultures in about six hours, enabling faster, targeted antibiotic therapy and addressing the global challenge of antimicrobial resistance. Founded in 2008 and headquartered in Uppsala, the company is listed on Nasdaq Stockholm and targets healthcare providers seeking advanced, time-critical diagnostics solutions.
YTD Price Performance: 16.28%
Average Trading Volume: 12,235
Technical Sentiment Signal: Sell
Current Market Cap: SEK540M
Learn more about QLINEA stock on TipRanks’ Stock Analysis page.